Guillain-Barré syndrome (GBS) is a rare autoimmune neuropathic disorder of peripheral nerves usually following an infection or on rarer occasions following vaccinations, but the exact underlying pathophysiology is still unclear. The most common etiology of GBS is a bacterial infection caused by Campylobacter jejuni. Viral infections like Zika virus, Epstein-Barr virus, and Cytomegalovirus also add to the list of GBS etiology. COVID-19 (SARS-CoV-2) has also been reported to cause GBS. Vaccines like the rabies vaccine, influenza vaccine, and poliovirus vaccine account for a very small fraction of Guillain-Barré syndrome. GBS as an adverse effect of COVID-19 vaccination was not reported by the Vaccine Adverse Event Reporting System (VAERS), but an update was later released in the course of the pandemic from FDA news, reporting several patients developing GBS after receiving the COVID-19 vaccine. In this case series, we discuss five cases that developed the GBS post-COVID-19 AstraZeneca vaccine, along with its pathophysiology, management, and outcome.

Renal angiomyolipoma is a benign mesenchymal tumor composing adipose tissue, smooth muscle, and blood vessels. Despite being benign, the tumor sometimes can be aggressive with a locoregional and venous extension. Here, we present a case of a 48-year-old female who presented with a lump in the abdomen for two months, which was initially small and gradually increased in size associated with pain. Ultrasound of abdomen-pelvis showed ill-defined heterogeneous lesion arising from left kidney showing few hypoechoic and calcific focus within it. Contrast-enhanced computed tomography suggested an exophytic mass lesion with a central scar and calcification measuring 13 x 11 cm indicating renal cell carcinoma. Based on the benign nature and being well encapsulated, the patient was taken up for a left radical nephrectomy. However, the final histologic assessment concurred with renal angiomyolipoma.